The Halifax Group has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is a global technology and scientific communication company focused on the pharma, biopharma and medical device industries. Halifax partnered with management to provide a significant equity investment. Financial terms were not disclosed.
 
Envision offers solutions including strategic publication planning and related data dissemination and consultancy services, along with technology solutions. Envision Pharma has two offices in the UK and three in the U.S. in Philadelphia, PA, Southport, CT, and Glastonbury, CT. The company has approximately 280 employees.
 
Envision’s chief executive officer, Brian Hepburn, said, “Thanks to the hard work of our employees and enduring commitment of our customers, we successfully navigated our sale process and are excited to begin our next phase of growth in partnership with the Halifax team. Halifax’s proven expertise in pharma and health services made them the ideal partner of choice for our company, and their involvement will enable us to invest in several new innovative platforms and related services to further support the evolving needs of our clients.”
 
“Envision provides industry-leading technology and services to many of the world’s foremost pharmaceutical and medical technology companies,” said David Dupree, managing director at Halifax. “These compliance-driven services are critical to the pharmaceutical development and commercialization process, and we believe the company is well-positioned to build on its 12-year track record of success.”